大鼠中胰岛、心脏、肾脏和皮肤同种异体移植在有或无增强情况下的比较存活情况。

Comparative survival of pancreatic islets, heart, kidney, and skin allografts in rats, with and without enhancement.

作者信息

Nash J R, Peters M, Bell P R

出版信息

Transplantation. 1977 Jul;24(1):70-3. doi: 10.1097/00007890-197707000-00010.

DOI:10.1097/00007890-197707000-00010

Abstract

Enhancement of (AS X Aug)F1 pancreatic islet allograft survival in diabetic AS rats was achieved by treating the recipient with a course of antidonor antiserum. Their survival in both untreated and treated recipients was compared with the survival of transplanted heart, kidney, and skin allografts similarly treated. The islet allografts in the untreated group were rejected by a mean of 3.2 days whereas the other allografts were rejected by a mean of 8.3 days. In the enhanced group all of the kidney allografts, 7 of 11 heart allografts, and 4 of 10 islet allografts had a prolonged survival, whereas none of the skin allografts had a prolonged survival. Islet allografts are thus more susceptible to rejection than other tissues, but their survival can be prolonged using specific immunosuppression. The reasons for the increased susceptibility to rejection are discussed.

摘要

通过用一个疗程的抗供体抗血清治疗受体，实现了糖尿病AS大鼠中（AS×奥格）F1胰腺胰岛同种异体移植存活期的延长。将未治疗和治疗后的受体中胰岛同种异体移植的存活情况与同样处理的心脏、肾脏和皮肤同种异体移植的存活情况进行了比较。未治疗组的胰岛同种异体移植平均在3.2天被排斥，而其他同种异体移植平均在8.3天被排斥。在增强组中，所有肾脏同种异体移植、11个心脏同种异体移植中的7个以及10个胰岛同种异体移植中的4个存活期延长，而皮肤同种异体移植均未出现存活期延长。因此，胰岛同种异体移植比其他组织更容易被排斥，但使用特异性免疫抑制可延长其存活期。文中讨论了对排斥易感性增加的原因。